Anthem Biosciences IPO Subscribed 67.42x on Day 3, QIB Leads with 192.80x Demand

Anthem Biosciences' initial public offering (IPO) has demonstrated robust investor demand through its third and final day of subscription, with Anthem Biosciences' stock price set at ₹570 per share reflecting positive market reception. The ₹3,395.00 crore IPO reached 67.42 times by 4:59:33 PM on day three, indicating strong investor interest in this contract research and manufacturing organisation incorporated in 2006.

Anthem Biosciences IPO qualified institutional buyers segment leads with exceptional 192.80 times subscription, whilst non-institutional investors demonstrate solid participation at 44.70 times and retail investors show measured interest at 5.98 times, reflecting strong institutional confidence in this company.

Anthem Biosciences IPO subscription reached 67.42 times on day three, led by QIB (192.80x), NII (44.70x), and Retail Investors (5.98x). Total applications reached 37,94,038.

Subscription Status of Anthem Biosciences IPO:

Here are the subscription details for Anthem Biosciences IPO as of Day 3 (July 16, 2025, 4:59:33 PM):

Key Highlights - Day 3:

• Overall subscription reaching strong 67.42 times, a remarkable surge from day two's 3.48 times
• QIB segment leading with exceptional demand at 192.80 times, dramatically building from day two's 0.62 times
• Institutional confidence witnessed massive surge on final day, addressing earlier concerns
• NII segment demonstrating solid participation at 44.70 times, substantially increasing from day two's 10.26 times
• bNII category showing robust participation at 51.66 times, reflecting strong high-net-worth investor appetite
• Retail investors showing measured improvement at 5.98 times, building from day two's 2.21 times
• Employee segment showing moderate participation at 6.99 times despite ₹50 discount offered
• sNII category displaying steady interest at 30.80 times, indicating broad-based smaller HNI participation
• Final day transformation from institutional caution to overwhelming confidence
• Total applications reached 37,94,038, indicating substantial investor participation for this mainboard IPO
• Cumulative bid amount reached ₹1,60,451.06 crores against the issue size of ₹3,395.00 crores
   

Anthem Biosciences IPO - Day 2 Subscription at 3.48 Times

Key Highlights - Day 2:

• Overall subscription improving to 3.48 times from day one's 0.77 times
• NII segment demonstrating strong growth at 10.26 times, building momentum from day one's 1.64 times
• Retail investors showing moderate improvement at 2.21 times, building from day one's 0.62 times
• QIB segment showing minimal improvement at 0.62 times, indicating continued institutional caution
   

Anthem Biosciences IPO - Day 1 Subscription at 0.77 Times

Key Highlights - Day 1:

• Overall subscription opening poorly at 0.77 times, showing disappointing initial investor interest
• NII segment leading early participation at 1.64 times, indicating modest high-net-worth sentiment
• Retail investors showing weak early interest at 0.62 times, reflecting cautious retail approach
• QIB segment showing poor participation at 0.39 times, reflecting initial institutional concern
• Employee segment displaying moderate interest at 1.04 times with discount benefit
   

About Anthem Biosciences Limited

Incorporated in 2006, Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organisation with fully integrated operations encompassing drug discovery, development, and manufacturing processes. The company serves diverse customers, including innovative, emerging biotech firms and large pharmaceutical companies on a global scale, manufacturing specialised fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.